News | Endovascular Aortic Repair | February 23, 2021

Medtronic Recalls Unused Valiant Navion Thoracic Stent Grafts

Physicians directed to immediately cease use of the Medtronic Valiant Navion thoracic stent graft system

Medtronic Recalls Unused Valiant Navion Thoracic Stent Grafts

February 23, 2021 — Medtronic has voluntarily issued a global recall of unused Medtronic Valiant Navion thoracic stent graft system and informed physicians to immediately cease use of the device until further notice.

Medtronic initiated this action in response to information recently obtained from the Valiant Evo Global Clinical Trial indicating that three patients in the Valiant Evo Global Clinical Trial were observed to have stent fractures. Two of these stent fractures resulted in confirmed type IIIb endoleaks. One patient death was reported, the company said.

Following these observations, an independent imaging laboratory reviewed all available images from patients enrolled in the Valiant Evo Global Clinical Trial. Upon further analysis of the images, seven out of 87 patients were observed to have stent ring enlargement beyond the design specification. Those observations require further assessment to determine potential clinical importance.

Medtronic is currently conducting a comprehensive technical root cause investigation, including further review of follow-up clinical trial imaging and commercial complaints and imaging.

"There is nothing more important than the safety and well-being of patients," said Nina Goodheart, senior vice president and president, structural heart and aortic, part of the Cardiac Vascular Group at Medtronic. "We treat matters of product safety with the highest priority and urgency. Our decision to implement this voluntary recall is necessary to ensure the utmost patient safety. As our investigation continues, we are committed to timely communication with physicians and regulatory bodies."

Medtronic has contacted the U.S. Food and Drug Administration (FDA), along with other regulatory bodies around the world, to share information related to this issue. Medtronic will continue working directly with regulatory authorities on this global voluntary recall.

Patient Management Recommendations for Those Implanted With the Valiant Navion

Patients with a Medtronic Valiant Navion thoracic stent graft system should consult their physician with any questions.

As part of the voluntary recall of unused product, physicians were sent written communication from Medtronic directing them to immediately cease use of the Medtronic Valiant Navion thoracic stent graft system and instructions for returning unused product to Medtronic.

Medtronic advises physicians to retrospectively review all available images of patients treated with Valiant Navion thoracic stent graft system with specific attention to stent fractures and type IIIb endoleaks and contact Medtronic if any imaging findings are observed.

Medtronic urges physicians to follow best clinical practices and evaluate patients with at least annual follow-up according to the imaging recommendations in the Medtronic Valiant Navion thoracic stent graft system Instructions for Use (IFU).

As always, physicians are asked to notify Medtronic of any adverse events or product safety issues associated with use of any Medtronic product, which also should be reported to the FDA's MedWatch Adverse Event Reporting program. Outside of the U.S. adverse events or product safety issues associated with use of any Medtronic product should be reported to the appropriate competent authority.

For more information: www.medtronic.com


Related Content

Feature | Cardiovascular Business | By Merilee Kern, MBA

Numerous indicators make clear that the next five years will usher in extreme transformation for a multitude of ...

Home November 09, 2022
Home
News | Cardiovascular Business

November 1, 2022 — Deepak L. Bhatt, MD, MPH, a top expert in cardiovascular medicine and interventional cardiology, has ...

Home November 01, 2022
Home
Feature | Cardiovascular Business

November 1, 2022 — Johnson & Johnson and Abiomed, a world leader in breakthrough heart, lung and kidney support ...

Home November 01, 2022
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

Here is what you and your colleagues found to be most interesting in the fields of diagnostic and interventional ...

Home November 01, 2022
Home
News | Cardiovascular Business

October 31, 2022 — The Yale School of Medicine announced the passing of Robert W. Berliner Professor Emeritus of ...

Home October 31, 2022
Home
News | Cardiovascular Business

October 24, 2022 — Asher Kimchi, MD, clinical chief of Cardiology, vice-clinical chief of the Department of Medicine ...

Home October 24, 2022
Home
News | Cardiovascular Business

October 20, 2022 — Atlas Healthcare Partners – which specializes in developing and managing ambulatory surgery centers ...

Home October 20, 2022
Home
News | Cardiovascular Business

October 19, 2022 — Mount Sinai Health System’s globally acclaimed cardiologist Valentin Fuster, MD, PhD, has been named ...

Home October 19, 2022
Home
News | Cardiovascular Business

October 12, 2022 — HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D-vector ECG ...

Home October 12, 2022
Home
News | Cardiovascular Business

October 6, 2022 – OpSens Inc., a Quebec-based medical device cardiology-focused company, has announced that it has ...

Home October 06, 2022
Home
Subscribe Now